Effect of Intraperitoneal Dexmedetomidine on Postoperative Pain after Cesarean Section

Comparison of the Effect of Intraperitoneal Dexmedetomidine and Normal Saline on Postoperative Pain Severity after Elective Cesarean Section in Pregnant Women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260216068880N1

Enrollment

Registered

2026-03-31

Start date

2026-04-04

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain after cesarean section. Encounter for cesarean delivery without indication

Interventions

Intervention 1: Intervention group: Dexmedetomidine, manufactured by Shahid Ghazi Pharmaceutical Company (Tabriz, Iran), administered intraperitoneally at a dose of 1 µg/kg, diluted in 40 mL of normal

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women aged 18 to 40 years Undergoing elective cesarean section under spinal anesthesia ASA physical status II Second cesarean delivery Ability to understand and report pain using Visual Analog Scale Provision of written informed consent

Exclusion criteria

Exclusion criteria: Emergency cesarean section Preterm pregnancy Age below 18 or above 40 years History of allergy to dexmedetomidine Underlying systemic diseases Use of analgesics or sedatives within 24 hours before surgery Refusal to participate

Design outcomes

Primary

Measure	Time frame
Postoperative pain severity after cesarean section. Timepoint: Immediately after recovery and every 15 minutes up to 3 hours after surgery. Method of measurement: Visual Analogue Scale for pain assessment.	—

Secondary

Measure	Time frame
Postoperative opioid consumption. Timepoint: During recovery period up to 3 hours after surgery. Method of measurement: Total dose of administered pethidine recorded in milligrams.;Postoperative blood pressure. Timepoint: Before intervention and every 15 minutes up to 3 hours after surgery. Method of measurement: Measured using a standard calibrated blood pressure monitoring device.;Arterial oxygen saturation. Timepoint: Before intervention and every 15 minutes up to 3 hours after surgery. Method of measurement: Measured using a standard pulse oximeter.;Postoperative nausea and vomiting. Timepoint: During recovery period up to 3 hours after surgery. Method of measurement: Clinical assessment based on presence or absence of nausea and vomiting.;Postoperative shivering. Timepoint: During recovery period up to 3 hours after surgery. Method of measurement: Clinical assessment based on presence or absence of shivering.	—

Measure

Time frame

Postoperative opioid consumption. Timepoint: During recovery period up to 3 hours after surgery. Method of measurement: Total dose of administered pethidine recorded in milligrams.;Postoperative blood pressure. Timepoint: Before intervention and every 15 minutes up to 3 hours after surgery. Method of measurement: Measured using a standard calibrated blood pressure monitoring device.;Arterial oxygen saturation. Timepoint: Before intervention and every 15 minutes up to 3 hours after surgery. Method of measurement: Measured using a standard pulse oximeter.;Postoperative nausea and vomiting. Timepoint: During recovery period up to 3 hours after surgery. Method of measurement: Clinical assessment based on presence or absence of nausea and vomiting.;Postoperative shivering. Timepoint: During recovery period up to 3 hours after surgery. Method of measurement: Clinical assessment based on presence or absence of shivering.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Moradi

Karaj University of Medical Sciences

moradifatemeh2020@gmail.com+98 71 4331 5233

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026